

Nutriband's Innovative Patent Breaks New Ground in Transdermal Medications

Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) announces the issuance of a U.S. patent for its cutting-edge AVERSA™ Technology.


ORLANDO, FL, USA, September 20, 2023 /EINPresswire.com/ -- [Nutriband](https://www.nutriband.com/) Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a leading developer of transdermal pharmaceutical products, proudly announces the issuance of a U.S. patent for its cutting-edge [AVERSA™](https://www.nutriband.com/aversa)

Technology. This groundbreaking innovation, utilizing taste aversion, marks a paradigm shift in addressing the primary routes of abuse associated with opioid-based transdermal patches.

The newly granted patent, numbered [U.S. patent 11,759,431](https://www.uspto.gov/patents/publications/11759431), titled "Abuse and Misuse Deterrent Transdermal Systems," significantly bolsters Nutriband's intellectual property protection in the United States. It covers a range of abuse deterrent transdermal products, all rooted in the proprietary AVERSA™ abuse deterrent technology. This pioneering technology seamlessly integrates into transdermal patches, effectively countering abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.

Nutriband's flagship product in development, AVERSA™ Fentanyl, leads the charge in revolutionizing pain management. It aims to become the market's premier abuse deterrent pain patch, setting new standards for safety. This patent signifies a pivotal milestone in Nutriband's strategic vision to fortify its intellectual property foundation around its proprietary abuse deterrent technology. With a global reach encompassing 45 countries, Nutriband's IP portfolio solidifies its position in the market. AVERSA™ Fentanyl, the company's flagship product, recently projected peak annual U.S. sales ranging from \$80M to \$200M.

Nutriband's AVERSA™ abuse deterrent transdermal technology presents a transformative solution to enhance the safety profile of transdermal drugs susceptible to abuse. AVERSA™ not only ensures continued access for patients in need but also minimizes the risk of abuse, diversion, misuse, and accidental exposure. Backing this pioneering technology is a robust



intellectual property portfolio, with patents granted in various countries, including the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.

About Nutriband Inc.

Nutriband Inc. is a leader in developing transdermal pharmaceutical products. At the forefront is the company's flagship product, an abuse deterrent fentanyl patch incorporating the groundbreaking AVERSA™ abuse-deterrent technology. AVERSA™ technology can be seamlessly integrated into any transdermal patch to counteract abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

For more information, visit www.nutriband.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements. Factors that may cause such differences include the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system, obtain patent protection for its abuse technology, secure necessary financing, obtain regulatory approvals, and market its products effectively. The Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances that may arise after the date hereof.

David Zazoff

Amplifi / Plato

+1 551-574-2169

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/656620012>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.